These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30395832)

  • 1. Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic Proteins.
    Wang YC; Wang Y; Schrieber SJ; Earp J; Thway TM; Huang SM; Zineh I; Christl L
    J Pharm Sci; 2019 Jan; 108(1):73-77. PubMed ID: 30395832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.
    Zhu P; Sy SKB; Skerjanec A
    AAPS J; 2018 Mar; 20(2):40. PubMed ID: 29516330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development.
    Li F; Sun Q; Du S; Florian J; Wang Y; Huang SM; Zineh I; Wang YC
    Clin Pharmacol Ther; 2023 Jan; 113(1):62-70. PubMed ID: 36000498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies.
    Obianom ON; Okusanya OO; Earp J; Thway TM
    Clin Pharmacol Ther; 2020 Jul; 108(1):107-115. PubMed ID: 31957006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.
    Song F; Zheng X; Wang Y; Chow SC; Sun H
    AAPS J; 2021 Nov; 24(1):3. PubMed ID: 34850298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity.
    Makarenko I; Petrov A; Belova B; Saparova V; Arefeva A; Peskov K; Kudryashova N; Khokhlov A; Drai R
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):419-431. PubMed ID: 38168134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Switching on Pharmacokinetics of Therapeutic Biologics and Interchangeability Assessment-A Simulation Study.
    Ji P; Ren Y; Li L; Schrieber SJ; Pisal D; Hallett W; Wang Y; Sahajwalla CG
    J Clin Pharmacol; 2022 Jan; 62(1):36-45. PubMed ID: 34411322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.